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ABSTRACT. The study spans over-identification of phytochemicals suited for
treatment of COVID-19. The study focuses on the chemical that has a tendency to
bind with Human ACE2 protein and two of the main Sars-Cov-2 proteins which are
the Spike protein and the RNA-directed RNA polymerase (RdRp) protein. After
screening a large list of phytochemicals two of the compound i.e. Kansuinine B and
Digitoxin were found to have promising traits for the treatment of COVID-19. Both
the compounds have been in use for centuries. Digitoxin was extracted from
Foxglove seeds in 18th century for heart-related illnesses. Kansuinine B originates
from a Chinese herb Euphorbia Kansui (E. Kansui) E. Kansui has been widely used
in herbal medicine for a multitude of illnesses including lungs related diseases.
Studies also show that it has the ability to suppress cytokine response through the
expression of the SOCS3 gene. In-silico simulations show that both these
compounds have a better affinity and binding properties with these three proteins as
compared to many other drugs under trial for COVID-19 like Remdesivir,
Ritonavir, Famotidine, Camostat Mesylate, and Hesperidin. A treatment based on
the combination of both compounds can be very effective. Any self-medication of
both the compounds is highly discouraged as misuse of both the compounds can be
very harmful.
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1. Introduction. COVID-19 is the pneumonia caused by the virus called Sars-Cov-2. This virus belongs to
the corona virus family. Previously known viruses of this family cause diseases like SARS (Severe Acute
Respiratory Syndrome) and MERS (Middle East Respiratory Syndrome). Out of all these diseases COVID-19
has proven to be most infectious and deadly. It has the potential to spread at an exponential rate. If
uncontrolled almost 70% of the population can get infected. Furthermore, the novel corona virus is greater
threat because the population at large has never been exposed to this virus and hence have no immunity
against it. The Coronavirus pandemic has emerged as one of the greatest challenge of the century.
Virus is an organism that lies at the edge life. It can be transmitted through several ways. Generally, they
spread through air, water and bodily fluids like blood. Sars-Cov-2 is spread through the aerosol of infected
person. Furthermore, it can live on surfaces on which droplets from coughing or sneezing of an infected
person fall. On such surfaces the viral structure can survive for prolonged periods of up to 72 hours. Anybody
who touches such a surface can get himself infected. Simplest preventive measure is to wash hands frequently
and not to touch surfaces in public use.
Antibiotics are used to counter pathogens like bacteria but bears no effect on viruses. No medicine
has been found that can kill virus and hence clear it from the system. Vaccines are used as a preventive
measure. Basically, vaccines are deactivated pathogens which train the immune system to generate a response
against them. This leads to generation of antibobies against the pathogens. Moreover, the B- and T-cells get
trained to generate a immune response against these pathogens. Some of the infections like HPV and HIV can
evade the immune response which makes it impossible to find a vaccine against them. Anti-viral drugs are
used to cope with such situations. Anti-viral drugs mechanism works by targeting specific proteins of the viral
structure. These proteins may either be linked with reproduction of virus or its underlying mechanism for
entry into human cell structure. Anti-viral drugs interacts with key structural and non-structural proteins of the
virus to inhibit its function. This inhibition prevents the virus to either replicate or damage human cells.
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Phyto-chemicals are well tolerated substances which have been in use since centuries. Most of them are well
tolerated and their side effects if any are well known. Many phyto-chemicals are known to have anti-viral
properties. A range of potent phytochemical such as flavonoids, organosulfur compounds, lignans, terpenoids,
sulphides, limonoids, polyphenolics, chlorophyllins, coumarins, furyl compounds, saponins, alkaloids,
thiophenes, polyines, proteins and peptides have been found to have therapeutic effects against a cohort of
viruses. Many public chemical databases like PubChem lists a large number of phytochemicals. Analytical
and Laboratory trials require a long time taking process for finding appropriate drug. This process can be
immensely expedited. This study uses efficient and accurate modeling techniques of simulating the effects of
compounds on proteins. This method provides a faster and robust answer regarding the appropriateness of a
chemical.
2. Materials and Methods Fundamental work regarding the discovery of these phytochemicals was
obtaining the genome of the Sars-Cov-2 virus. Subsequently, the genomic primary protein structure as well as
3D structure has also been formed [1]. Fig 1. shows the 3D structure of genomic protein of Sars-Cov-2 while
Fig2 shows the Spike protein of Sars-Cov-2.
Figure 1 Genomic Protein of Sars-Cov-2
Figure 2 Spike protein of Sars-Cov-2
The spike protein of Sars-Cov-2 acts as a receptor for Human ACE2 protein given in Figure 3. The ACE2
proteins forms the outer membrane of the lungs. Fig 3 shows the 3D structure of ACE2 human protein.
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Figure 3 Shows the ACE2 Human protein
Once the virus gain entry into a cell it uses the cell resources to replicate itself making the cell sick and
leading to its eventual death. The RNA structure of the virus is replicated by the RNA-directed RNA
polymerase (RdRp) protein through its genome transcription. The tertiary structure of the RdRp protein is
illustrated in figure 4.
Figure 4 RdRp Protein of Sars-Cov-2
Numerous possibilities are explored to find a phytochemical that has antiviral effect against Sars-Cov-2.
Phytochemicals that bind with the spike protein can prevent it from anchoring itself with the lungs,
phytochemicals that binds with ACE2 protein also have same effect. The proteins that bind with RdRp protein
can prevent replication of virus.
The structure of 2400 phytochemicals listed on PubChem [2] was used to compute their affinity
with the three target proteins. To validate the work the affinity of currently under trail drugs for COVID-19
was also estimated. Many researchers have used mathematical and artificially intelligent models to study
proteomic properties [3-28]. Based on virtual drug discovery models the listed phytochemicals were screened.
Their affinity with the given three receptors was thoroughly probed. An affinity value of less than -7 is
considered promising. Such promising compounds were further investigated for binding site attributes.
3. Results. The work focuses on discovering the most appropriate substance that could mimic an antiviral
effect against COVID-19. It is about finding the right chemical or a combination of chemical which is like a
brute force search. After thorough screening and detailed computational analysis two compounds were found
to be promising with considerably better affinity. Furthermore, their interaction is compared with the
interaction of other compounds being actively pursued in different trials like Hydroxychloroquine, Camostat
Mesylate, Hesperidin, Ritonavir, Famotidine and Remdesivir. The two compounds identified are
1) Digitoxin (PubChem ID 441207)
2) Kansuinine B (PubChem ID 442050)
The affinity of compounds along with binding sites with RdRp, Human ACE2 and Spike proteins are listed in
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Table1, 2 and 3 respectively.
Table 1 Binding of RdRp Protein with compounds
Ligand Name Binding
Residue 1
Distance
Residue 1
Binding
Residue 2
Distance
Rsidue 2
Binding
Afinity
Digitoxin ARG-173 2.8 TYR-346 2.5 -10.3
Kansuinine B TYR-69 2 ARG-118 1.4 -19.3
Camostat Mesylate TYR 346 2 - - -6.8
Hesperidin THR 394 2.5 PHE 396 2.7 -8.4
Ritonavir ASP 208 2.5 SER 6 2.1 -8
Famotidine ASP-760 2.5 TRP-800 2.2 -6
Remdesivir ARG-249 2 ARG-349 2.2 -8.1
Hydroxychloroquine GLY-327 2.7 HIS-347 2.3 -6.3
Table 2 Human ACE2 protein Bindings with compounds
Ligand Name Binding
Residue 1
Distance
Residue 1
Binding
Residue 2
Distance
Rsidue 2
Binding
Afinity
Digitoxin ASP-349 2.2 SER-43 2.5 -10.7
Kansuinine B ALA 348 2.8 SER 47 1.7 -17
Camostat Mesylate TYR 385 2.1 LEU 73 2.9 -7.6
Hesperidin ASP 382 2.6 LYS 562 2.1 -9.8
Ritonavir ASP 350 2.4 SER 42 2.6 -8.8
Famotidine ASP-543 2.8 SER-547 2.6 -6.2
Remdesivir ARG-514 2.5 ASN-394 2.1 -7.7
Hydroxychloroquine ARG-393 2.2 ASP-350 2 -6.4
Table 3 Interaction of Spike protein with compounds
Ligand Name Binding
Residue 1
Distance
Residue 1
Binding
Residue 2
Distance
Residue 2
Binding
Afinity
Digitoxin ARG-1014 2.5 GLN-314 3.4 -10.2
Kansuinine B THR 778 2.2 LYS 733 2.7 -18.9
Camostat Mesylate ARG 1039 2.5 ASN 1023 2.1 -8.2
Hesperidin GLN 1113 2.2 GLN 913 2.3 -9.7
Ritonavir No Bonding No Bonding -8.3
Famotidine ASP-745 2.7 CYS-743 2.5 -6.5
Remdesivir TYR-756 2.9 ARG-995 2.5 -8
Hydroxychloroquine ASP-350 3.5 PHE-970 2.5 -7
Above tables show that the affinity of Digitoxin and Kansuinine B are higher than other compounds being
tested in various trials. Moreover, the effect of Digitoxin on Spike protein seems noteworthy as it binds to a
huge span of the protein. This is a strong indication that Digitoxin can induce an active role in inhibiting the
function of spike protein. Kansuinine B shows good ability to bind with HumanACE2 protein makes is
suitable for prophylactic use. The binding of these compounds is illustrated in below diagrams.
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Conclusion. Simulations show that both the compounds have promising attributes which makes them a good
candidate for the treatment of COVID-19. They have the highest affinity. Digitoxin and Kansuinine B binds to
RdRp protein at different residue sites covering a significant part of protein. This suggests that their combined
use can inhibit the operation of RdRp protein significantly. RdRp protein is responsible for replication of the
virus once it gains entry into the cell. Inhibition of RdRp will impede this replication process. Moreover,
Kansuinine B exhibits good binding with Human ACE2 protein. This indicates that that it also has
prophylactic effect. A comparison of affinity and binding sites is shown for some other compounds currently
subject of various trials. The overall comparison among these compounds indicates that both these
compounds have highest affinity with key proteins and the combination is a potential drug for COVID-19.
Kansuinine B
Kansuinine B is diterpenoids found in the Chinese herb Euphorbia Kansui (E. Kansui), it is also locally called
Gan Sui. In Chinese herbal medicine it has been used since ages for edema, cough, accumulation of pathogens
in lungs, dysuria and constipation. One study shows that use of Euphorbia Kansui suppresses the Cytokine
response through expression of SOCS3 gene. Immense cytokine response namely the Cytokine storm is
considered as the main factor that causes death in old age COVID-19 patients [22]. Hence, this is another
additional factor that supports the use of E. Kansui for COVID-19 treatment.
Figure 5 Interaction of Digitoxin with (a)
RdRp, (b) Human ACE2 and (c) Spikeproteins.
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Figure 6 Interaction of Kansuinine B with (a) RdRp, (b) Human ACE2 and (c) Spike Proteins
Digitoxin
It is a compound found in an herb called Foxglove (Digitalis Purpurea). It was first extracted in 18th century
to be used for heart condition. It was used for treatment of atrial fibrillation. Now its derivative Digioxin is
used for the same purpose.
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